Literature DB >> 15277615

Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese.

L Bian1, J D Yang, T W Guo, Y Sun, S W Duan, W Y Chen, Y X Pan, G Y Feng, L He.   

Abstract

BACKGROUND: The gene for insulin-degrading enzyme (IDE) represents a strong positional and biologic candidate for late-onset Alzheimer disease (LOAD) susceptibility. IDE is located on chromosome 10q23.3 close to a region of linkage for LOAD. In addition, many studies have identified a possible role of IDE in the degradation of amyloid beta-protein and the intracellular amyloid precursor protein (APP) domain released by gamma-secretase processing.
OBJECTIVE: To examine the association of IDE with AD in the Han Chinese.
METHODS: Four IDE polymorphisms (three in 5'-untranslated region and one in intron 21) were analyzed, using a population of 210 patients with LOAD and 200 control subjects well matched for age, sex, and ethnic background.
RESULTS: Among the four polymorphisms studied, only the C allele of single-nucleotide polymorphism (SNP) IDE2 showed association with AD (p = 0.005). Stratification of the data by APOE epsilon4 status indicated that the association between IDE2 and AD was confined to APOE epsilon4 carriers only. No association was found between all variants studied and AD within APOE epsilon4-negative subjects. The global haplotype frequencies showed significant differences between AD patients and control subjects. Furthermore, overrepresentation of GCTG haplotype in the AD group was found. It may be a risk haplotype for AD.
CONCLUSIONS: These results suggest a possible synergic interaction between IDE and APOE epsilon4 in the risk to develop late-onset sporadic AD. IDE might modify the effect of the APOE epsilon4 risk factor in the Han Chinese population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277615     DOI: 10.1212/01.wnl.0000129987.70037.db

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population.

Authors:  Saila Vepsäläinen; Michele Parkinson; Seppo Helisalmi; Arto Mannermaa; Hilkka Soininen; Rudolph E Tanzi; Lars Bertram; Mikko Hiltunen
Journal:  J Med Genet       Date:  2007-05-11       Impact factor: 6.318

2.  Brain structure and obesity.

Authors:  Cyrus A Raji; April J Ho; Neelroop N Parikshak; James T Becker; Oscar L Lopez; Lewis H Kuller; Xue Hua; Alex D Leow; Arthur W Toga; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2010-03       Impact factor: 5.038

3.  In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.

Authors:  Wei-Jie Zhang; Xiao Luo; Zhan-Yun Guo
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

4.  17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.

Authors:  Liqin Zhao; Jia Yao; Zisu Mao; Shuhua Chen; Yan Wang; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2010-01-06       Impact factor: 4.673

5.  Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.

Authors:  Hui-Zhen Wang; Rui Bi; Deng-Feng Zhang; Guo-Dong Li; Xiao-Hong Ma; Yiru Fang; Tao Li; Chen Zhang; Yong-Gang Yao
Journal:  Mol Neurobiol       Date:  2015-09-11       Impact factor: 5.590

Review 6.  Prions: protein only or something more? Overview of potential prion cofactors.

Authors:  Carlo Fasano; Vincenza Campana; Chiara Zurzolo
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  beta-Amyloid degradation and Alzheimer's disease.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  J Biomed Biotechnol       Date:  2006

Review 8.  Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment.

Authors:  Moon K Song; David S Bischoff; Albert M Song; Koichi Uyemura; Dean T Yamaguchi
Journal:  BBA Clin       Date:  2016-10-02

9.  Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease.

Authors:  Minerva M Carrasquillo; Olivia Belbin; Fanggeng Zou; Mariet Allen; Nilufer Ertekin-Taner; Morad Ansari; Samantha L Wilcox; Mariah R Kashino; Li Ma; Linda H Younkin; Samuel G Younkin; Curtis S Younkin; Toros A Dincman; Melissa E Howard; Chanley C Howell; Chloe M Stanton; Christopher M Watson; Michael Crump; Veronique Vitart; Caroline Hayward; Nicholas D Hastie; Igor Rudan; Harry Campbell; Ozren Polasek; Kristelle Brown; Peter Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Patrick G Kehoe; David M Mann; A David Smith; Helen Beaumont; Donald Warden; Clive Holmes; Reinhard Heun; Heike Kölsch; Noor Kalsheker; V Shane Pankratz; Dennis W Dickson; Neill R Graff-Radford; Ronald C Petersen; Alan F Wright; Steven G Younkin; Kevin Morgan
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

10.  IDE Gene Polymorphism Influences on BPSD in Mild Dementia of Alzheimer's Type.

Authors:  Noriko Sato; Akinori Ueki; Hideo Ueno; Hidetaka Shinjo; Yoshio Morita
Journal:  Curr Gerontol Geriatr Res       Date:  2008-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.